Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Wang, L., Feng, L
More recent preclinical work has examined GHK-Cu in rodent models of pulmonary fibrosis, silicosis and airway remodelling, with oxidative stress and inflammatory signalling as the reported endpoints
They helped, until they thinned your skin and stopped working
Model Is the work done in isolated cells, in animals, or in humans Human data carry more weight for decisions that depend on actual outcomes Material Is the study using GHK Cu, GHK alone, or a vague copper peptide Does the methods section specify how the complex was prepared or verified Endpoint Is the primary outcome a molecular marker, a histology readout, or a clear clinical change such as wound closure speed or graded skin appearance Biomarkers can be useful, but they are not interchangeable with clinical outcomes Comparator Is there a placebo or vehicle control Is there a standard of care or another active comparator Exposure Are the doses or concentrations used in the experiment close to what could be achieved in a practical setting Some in vitro work uses concentrations that are orders of magnitude higher than those ever used in people Funding and conflicts Who funded the work Are there obvious commercial ties These factors do not automatically invalidate a study, but they do guide how skeptical a reader should be
Due to the persistent NF-B activation signaling present within the TME and even normal tissues, the loss of functional p53 leads to increased NF-B-dependent inflammatory gene expression
While these approaches help many people, a significant percentage find themselves managing chronic symptoms despite trying multiple interventions
